In today’s recent session, 7.07 million shares of the Eledon Pharmaceuticals Inc (NASDAQ:ELDN) have been traded, and its beta is 0.88. Most recently the company’s share price was $3.81, and it changed around $0.44 or 13.06% from the last close, which brings the market valuation of the company to $151.10M. ELDN at last check was trading at a discount to its 52-week high of $3.65, offering almost 4.2% off that amount. The share price’s 52-week low was $1.07, which indicates that the recent value has risen by an impressive 71.92% since then. We note from Eledon Pharmaceuticals Inc’s average daily trading volume that its 10-day average is 0.11 million shares, with the 3-month average coming to 67.30K.

Eledon Pharmaceuticals Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 6 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 0 recommended ELDN as a Hold, whereas 4 deemed it a Buy, and 0 rated it as Underweight. Eledon Pharmaceuticals Inc is expected to report earnings per share of -0.31 for the current quarter.

Eledon Pharmaceuticals Inc (NASDAQ:ELDN) trade information

Instantly ELDN has been showing a green trend so far today with a performance of 13.06% on intraday trading today. The performance over the last five days has remained in the green territory. The rise to weekly highs of 4.12 on recent trading dayincreased the stock’s daily price by 7.52%. The company’s shares are currently up 111.67% year-to-date, but still up 20.38% over the last five days. On the other hand, Eledon Pharmaceuticals Inc (NASDAQ:ELDN) is 53.01% up in the 30-day period. We can see from the shorts that 0.14 million shares have been sold at a short interest cover period of 2.2 day(s).

Eledon Pharmaceuticals Inc (ELDN) estimates and forecasts

Eledon Pharmaceuticals Inc share prices are performing particularly well not compared to other companies within the same industry. As is evident from the statistics, the company’s shares have risen 59.41 percent over the past six months and at a 7.32% annual growth rate that is well below the industry average of 17.50%. Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will gain 11.40% in revenue this quarter, and will report a decrease of -6.90% in the next quarter.

Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 29.97%.

ELDN Dividends

Eledon Pharmaceuticals Inc’s next quarterly earnings report is expected to be released on 2024-Nov-07.

Eledon Pharmaceuticals Inc (NASDAQ:ELDN)’s Major holders

Upon looking at major shareholders, it appears that insiders hold 0.07% of Eledon Pharmaceuticals Inc shares, and 46.06% of them are in the hands of institutional investors. The stock currently has a share float of 46.09%. Eledon Pharmaceuticals Inc stock is held by 37.0 institutions, with BVF INC/IL being the largest institutional investor. By 2024-06-30, it held 20.985% of the shares, which is about 6.29 million shares worth $16.61 million.

ARMISTICE CAPITAL, LLC, with 7.7894% or 2.34 million shares worth $6.17 million as of 2024-06-30, holds the second largest percentage of outstanding shares.

Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund were the top two Mutual Funds as of Jun 30, 2024. The former held 722.4 shares worth $2.77 million, making up 1.82% of all outstanding shares. On the other hand, Vanguard Extended Market Index Fund held roughly 367.28 shares worth around $1.41 million, which represents about 0.93% of the total shares outstanding.